Skip Navigation

European Heart Journal 1990 11(Supplement A):19-25; doi:10.1093/eurheartj/11.suppl_A.19
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kupper, W.
Right arrow Articles by Bleifeld, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupper, W.
Right arrow Articles by Bleifeld, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Sympathetic modulation in practice: the German clinical experience

W. Kupper, H.-H. Erlemeier and W. Bleifeld

Department of Cardiology, University Hospital Eppendorf Hamburg, F.R.G.

Address for correspondence: Professor W. Kupper, Department of Cardiology, Medical Clinic, University Hospital, Eppendorf, Martinistrasse 52, 2000 Hamburg 20, F.R.G.

Xamoterol is a β1-selective adrenoceptor partial agonist. The acute effects of xamoterol were studied in 30 patients with ischaemic heart failure. Haemodynamic data were assessed at baseline, at rest and after supine bicycle exercise (50 W for 3 min), and repeated 15 min after xamoterol(0.2 mg kg–1) given by infusion over 5 min.

At rest, xamoterol increased heart rate, mean blood pressure and cardiac index, and reduced pulmonary wedge pressure. On exercise, heart rate fell while cardiac index was maintained and pulmonary wedge pressure fell slightly but significantly. There was a tendency for plasma renin activity and plasma noradrenaline to fall both at rest and on exercise.

The clinical relevance of these haemodynamic and neurohumoral changes were examined in conjunction with thc German-Austrian Xamoterol Group's study, screening 443 patients with mild to moderate heart failure and giving xamoterol or placebo for 3 months as part of a randomized, double-blind study. The German experience was then placed in context of the pooled world-wide database of efficacy and safety in three other large (> 100 patients) studies with xamoterol in mild to moderate heart failure. In brief, this overview demonstrated a 2·98± 0·68 kJ improvement in work done over placebo, equivalent to 14% (xamoterol) and 6% (placebo) improvements over baseline (P < 0·0001).

Xamoterol is thus a promising new approach to the treatment of mild to moderate heart failure.

Key Words: Xamoterol • heart failure • haemodynamics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.